David’s reporting since 2001 has focused on the clinical aspects of medicine, particularly in the American health system. He’s covered everything from novel drugs for inflammatory bowel disease (think back to the advent of biologics!) to protocols for fine-tuning use of anticoagulants post-operatively, and from the fallout of medication compounding disasters to regulatory concerns about the 340B drug pricing program. He has covered dozens of medical conferences and profiled numerous clinicians and institutions. David is a native of Israel and lives in Toronto, Canada. His hobbies include playing music, gardening, camping and spending time with his wife, son and mini-Bernedoodle, Moishe.
Latest from David Wild
The last quarter of 2024 was flush with venture financings for biotechs finding novel ways to incorporate AI into their processes.
In Vivo speaks with Ashley Zehnder, CEO of Fauna Bio, a company using AI to identify drug targets based on natural disease resistance in animals.
As we enter 2025, In Vivo convened a group of biotech executives for a wide-ranging conversation about dealmaking this year and the challenges and opportunities for companies in the cardiometabolic, longevity, radiopharmaceuticals and cancer spaces. Essential listening before JPM.
In this episode of the In Vivo podcast, Harvard immunologist and co-founder of early-stage biotech Corner Therapeutics, Jonathan Kagan, talks about harnessing the power of the innate immune system by weaponizing dendritic cells and creating immunotherapies that are safer and more durable.
New alternative methods to animal testing in early drug development are increasing in sophistication and predictability, yet they are vastly underutilized. In Vivo presents an overview of select technologies and vendors.
The ability of artificial intelligence tools to distinguish correlation from causation could prove to be a boon to the industry.